Search

You searched for "Pelvic"

227 results found
The Journal of Urology cover image.

Pain relief after removal of non-obstructive renal calculi

4 March 2024 | | URO - Endourology & Stones
Non-obstructing stones are often not considered to be the source of pain, and probably most are not. This is because flank pain associated with a stone is typically caused by a stone that obstructs urinary flow, which increases intraluminal pressure...
The Journal of Urology front cover

Patterns of relapse and implications for post-nephrectomy surveillance in patients with high-risk NCC-RCC

1 September 2019 | | URO - Urologic Oncology
The natural history of non-clear cell renal cell carcinoma (NCC-RCC) post-nephrectomy with curative intent remains poorly defined. The surveillance protocols are largely dependent on guidelines followed for clear cell RCC (CC-RCC). In this study, the authors evaluated the relapse patterns...

Upper pole access is safe and effective for paediatric percutaneous nephrolithotomy

1 September 2018 | | URO - Paediatric Urology, URO - Urologic Oncology
Upper pole access for percutaneous nephrolithotomy (PCNL) provides a straight access tract to the ureter with easier placement of a guidewire, good exposure of the pelvis and upper ureter, and comfortable manipulations for the treatment of staghorn, large upper caliceal,...

Stepwise voltage ramping causes less renal haematomas than fixed maximal voltage ESWL

1 May 2016 | | URO - Endourology & Stones
Extracorporeal shock wave lithotripsy (ESWL) remains the recommended first line treatment for stones <2cm in the renal pelvis and upper or mid-pole calyces (Türk C, Knoll T, Petrik A, et al. European Association of Urology Guidelines on Urolithiasis. 2014). There...
The Journal of Urology cover image.

Long term outcomes of primary ureterovesicostomy for the primary obstructive megaureter

6 November 2024 | | URO - Paediatric Urology
Primary obstructive megaureter is dilatation of the ureter secondary to narrowing at the vesicoureteric junction (VUJ). Many (80%) require no intervention, however, a select number do for worsening hydroureteronephrosis, decreasing renal function, prolonged drainage time, recurrent urinary tract infections or...

Endoscopic management of upper tract urothelial carcinoma

1 January 2014 | | URO - Urologic Oncology
Upper tract urothelial carcinoma (UTUC) is a rare disease accounting for 5-10% of all urothelial carcinomas and has an annual incidence in Western countries of 1-2 per 100,000 [1,2]. It occurs more commonly in the pelvicalyceal system as opposed to...

Blaedderwaerc and other names

1 July 2016 | | URO - Infection, URO - Functional / Reconstructive Urology, URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). In the last article I said I would explore the history of something...

Can the latest patient decision aid help OAB patients?

8 January 2025 | | URO - Functional / Reconstructive Urology
OAB Answers is a patient decision aid co-authored by several European urologists and gynaecologists, and two patient advocates, to help patients understand and manage their overactive bladder (OAB). It is a 36-page document split into several clear sections, aiming to...

Bladder carcinoma MRI

1 September 2018 | | URO - Urologic Oncology, URO - Uroradiology
Bladder malignancy is one of the commonest malignancies of the renal tract, accounting for approximately 6% of male malignancy and 2% of female malignancy. The incidence increases with patient age with 70% of patients being over the age of 65...

Management of stage 1 non-seminomatous germ cell tumours

1 November 2014 | | URO - Urologic Oncology
Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

Neuroendocrine bladder tumour

5 February 2025 | | URO - Urologic Oncology
A 75-year-old male with a history of prostate adenocarcinoma (T3b/T4 N1 M1b, Gleason 4+3) on Zoladex® and enzalutamide, presented with visible haematuria. His prostate specific antigen (PSA) had decreased from 43.6ug/L in December 2022 to 0.02ug/L. He also had a...

Virtual reality: a novel approach to pain management during ESWL

4 March 2025 | | URO - Technology, URO - Endourology & Stones
Extracorporeal shock wave lithotripsy (ESWL) is a well-established treatment for kidney and ureteric stone disease, employing high-energy shock waves to fragment stones into smaller pieces for passage through the urinary tract. This article explores the application of virtual reality (VR)...